Overview

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Status:
Recruiting

Trial end date:
2025-08-31

Target enrollment:

Participant gender:

Summary

The goal of this study is to determine the recommended phase 2 dose of the multi-drug combination of abiraterone, cabozantinib, and nivolumab in conjunction with ongoing androgen deprivation therapy in previously untreated metastatic hormone-sensitive prostate cancer patients. The investigators hypothesize that the combination of cabozantinib and abiraterone acetate/prednisone in conjunction with nivolumab will have an acceptable safety profile and will be feasible to administer in patients with hormone-sensitive metastatic prostate cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

Bristol-Myers Squibb
Exelixis

Treatments:

Abiraterone Acetate
Nivolumab
Prednisone